The shaping and functional consequences of the dosage effect landscape in multiple myeloma

BMC Genomics

Volumn 14, Issue 1, 2013, Pages

  Samur, Mehmet K ^a,b   Shah, Parantu K ^a   Wang, Xujun ^c   Minvielle, Stéphane ^d   Magrangeas, Florence ^d   Avet Loiseau, Hervé ^d   Munshi, Nikhil C ^e   Li, Cheng ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b AKDENIZ UNIVERSITY   (Turkey)

^c TONGJI UNIVERSITY   (China)

^d NANTES UNIVERSITY HOSPITAL   (France)

^e VA BOSTON HEALTHCARE SYSTEM   (United States)

Author keywords

Copy number alteration; Dosage effect; Hyperdiploid; Integrative genomics; Multiple myeloma

Indexed keywords

APOPTOSIS GENE; ARTICLE; CANCER PROGNOSIS; CHROMOSOME; COPY NUMBER DOSAGE EFFECT; DOSAGE RESISTANT GENE; DOSAGE SENSITIVE GENE; DRIVER GENE; DRUG TARGETING; GENE; GENE DOSAGE; GENE EXPRESSION; GENE IDENTIFICATION; GENE REGULATORY NETWORK; GENE WISE DOSAGE EFFECT SCORE; GENOME WIDE KARYOTYPE PLOT; GENOMICS; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NUCLEOTIDE SEQUENCE; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; TRISOMY; CLUSTER ANALYSIS; COPY NUMBER VARIATION; DIPLOIDY; DNA MICROARRAY; EXON; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC DATABASE; GENETIC HETEROGENEITY; GENETICS; HUMAN CHROMOSOME; KARYOTYPING; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR GENE;

CHROMOSOMES, HUMAN; CLUSTER ANALYSIS; DATABASES, GENETIC; DIPLOIDY; DNA COPY NUMBER VARIATIONS; EXONS; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; GENETIC HETEROGENEITY; HUMANS; KARYOTYPING; MULTIPLE MYELOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; TRISOMY;

EID: 84884758943     PISSN: None     EISSN: 14712164     Source Type: Journal    
DOI: 10.1186/1471-2164-14-672     Document Type: Article

References (43)

1. Anderson KC, Carrasco RD. Pathogenesis of myeloma. Annu Rev Pathol 2011, 6:249-274. 10.1146/annurev-pathol-011110-130249, 21261519.
2. Avet-Loiseau H, Li C, Magrangeas F, Gouraud W, Charbonnel C, Harousseau JL, Attal M, Marit G, Mathiot C, Facon T, et al. Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol 2009, 27:4585-4590. 10.1200/JCO.2008.20.6136, 2754906, 19687334.
3. Munshi NC, Avet-Loiseau H. Genomics in multiple myeloma. Clin Cancer Res 2011, 17:1234-1242. 10.1158/1078-0432.CCR-10-1843, 3783001, 21411439.
4. Huang N, Shah PK, Li C. Lessons from a decade of integrating cancer copy number alterations with gene expression profiles. Brief Bioinform 2011, 13:305-316. 3357489, 21949216.
5. Gordon DJ, Resio B, Pellman D. Causes and consequences of aneuploidy in cancer. Nat Rev Genet 2012, 13:189-203.
6. Weaver BA, Cleveland DW. Does aneuploidy cause cancer?. Curr Opin Cell Biol 2006, 18:658-667. 10.1016/j.ceb.2006.10.002, 17046232.
7. Hede K. Which came first? Studies clarify role of aneuploidy in cancer. J Natl Cancer Inst 2005, 97:87-89. 10.1093/jnci/97.2.87, 15657335.
8. Holland AJ, Cleveland DW. Boveri revisited: chromosomal instability, aneuploidy and tumorigenesis. Nat Rev Mol Cell Biol 2009, 10:478-487. 3154738, 19546858.
9. Weaver BA, Cleveland DW. Aneuploidy: instigator and inhibitor of tumorigenesis. Cancer Res 2007, 67:10103-10105. 10.1158/0008-5472.CAN-07-2266, 3132555, 17974949.
10. Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C, Leyvraz S, Michallet M, Yakoub-Agha I, Garderet L, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 2007, 109:3489-3495. 10.1182/blood-2006-08-040410, 17209057.
11. Agnelli L, Mosca L, Fabris S, Lionetti M, Andronache A, Kwee I, Todoerti K, Verdelli D, Battaglia C, Bertoni F, et al. A SNP microarray and FISH-based procedure to detect allelic imbalances in multiple myeloma: an integrated genomics approach reveals a wide gene dosage effect. Genes Chromosomes Cancer 2009, 48:603-614. 10.1002/gcc.20668, 19396863.
12. Rudin CM, Durinck S, Stawiski EW, Poirier JT, Modrusan Z, Shames DS, Bergbower EA, Guan Y, Shin J, Guillory J, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet 2012, 44:1111-1116. 10.1038/ng.2405, 3557461, 22941189.
13. Cancer Genome Atlas Research N Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455:1061-1068. 10.1038/nature07385, 2671642, 18772890, Cancer Genome Atlas Research N.
14. Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM, Kalyana-Sundaram S, Wei JT, Rubin MA, Pienta KJ, et al. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 2007, 39:41-51. 10.1038/ng1935, 17173048.
15. Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, Beroukhim R, Milner DA, Granter SR, Du J, et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 2005, 436:117-122. 10.1038/nature03664, 16001072.
16. Akavia UD, Litvin O, Kim J, Sanchez-Garcia F, Kotliar D, Causton HC, Pochanard P, Mozes E, Garraway LA, Pe'er D. An integrated approach to uncover drivers of cancer. Cell 2010, 143:1005-1017. 10.1016/j.cell.2010.11.013, 3013278, 21129771.
17. Hungermann D, Schmidt H, Natrajan R, Tidow N, Poos K, Reis-Filho JS, Brandt B, Buerger H, Korsching E. Influence of whole arm loss of chromosome 16q on gene expression patterns in oestrogen receptor-positive, invasive breast cancer. J Pathol 2011, 224:517-528. 10.1002/path.2938, 21706489.
18. Sellmann L, Scholtysik R, Kreuz M, Cyrull S, Tiacci E, Stanelle J, Carpinteiro A, Nuckel H, Boes T, Gesk S, et al. Gene dosage effects in chronic lymphocytic leukemia. Cancer Genet Cytogenet 2010, 203:149-160. 10.1016/j.cancergencyto.2010.09.002, 21156227.
19. Monti S, Chapuy B, Takeyama K, Rodig SJ, Hao Y, Yeda KT, Inguilizian H, Mermel C, Currie T, Dogan A, et al. Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma. Cancer Cell 2012, 22:359-372. 10.1016/j.ccr.2012.07.014, 3778921, 22975378.
20. Roessler S, Long EL, Budhu A, Chen Y, Zhao X, Ji J, Walker R, Jia HL, Ye QH, Qin LX, et al. Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival. Gastroenterology 2012, 142:957-966. e912, 10.1053/j.gastro.2011.12.039, 3321110, 22202459.
21. Dickens NJ, Walker BA, Leone PE, Johnson DC, Brito JL, Zeisig A, Jenner MW, Boyd KD, Gonzalez D, Gregory WM, et al. Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome. Clin Cancer Res 2010, 16:1856-1864. 10.1158/1078-0432.CCR-09-2831, 2841345, 20215539.
22. Agnelli L, Bicciato S, Fabris S, Baldini L, Morabito F, Intini D, Verdelli D, Callegaro A, Bertoni F, Lambertenghi-Deliliers G, et al. Integrative genomic analysis reveals distinct transcriptional and genetic features associated with chromosome 13 deletion in multiple myeloma. Haematologica 2007, 92:56-65. 10.3324/haematol.10414, 17229636.
23. Agnelli L, Fabris S, Bicciato S, Basso D, Baldini L, Morabito F, Verdelli D, Todoerti K, Lambertenghi-Deliliers G, Lombardi L, Neri A. Upregulation of translational machinery and distinct genetic subgroups characterise hyperdiploidy in multiple myeloma. Br J Haematol 2007, 136:565-573. 10.1111/j.1365-2141.2006.06467.x, 17367409.
24. Chng WJ, Kumar S, Vanwier S, Ahmann G, Price-Troska T, Henderson K, Chung TH, Kim S, Mulligan G, Bryant B, et al. Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Res 2007, 67:2982-2989. 10.1158/0008-5472.CAN-06-4046, 17409404.
25. Birchler JA. Reflections on studies of gene expression in aneuploids. Biochem J 2010, 426:119-123. 10.1042/BJ20091617, 20141513.
26. Li C, Wong WH. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci USA 2001, 98:31-36. 10.1073/pnas.98.1.31, 14539, 11134512.
27. Lin M, Wei LJ, Sellers WR, Lieberfarb M, Wong WH, Li C. dChipSNP: significance curve and clustering of SNP-array-based loss-of-heterozygosity data. Bioinformatics 2004, 20:1233-1240. 10.1093/bioinformatics/bth069, 14871870.
28. Purdom E, Simpson KM, Robinson MD, Conboy JG, Lapuk AV, Speed TP. FIRMA: a method for detection of alternative splicing from exon array data. Bioinformatics 2008, 24:1707-1714. 10.1093/bioinformatics/btn284, 2638867, 18573797.
29. da Huang W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 2009, 37:1-13. 10.1093/nar/gkn923, 2615629, 19033363.
30. Kuijjer ML, Rydbeck H, Kresse SH, Buddingh EP, Lid AB, Roelofs H, Burger H, Myklebost O, Hogendoorn PC, Meza-Zepeda LA, Cleton-Jansen AM. Identification of osteosarcoma driver genes by integrative analysis of copy number and gene expression data. Genes Chromosomes Cancer 2012, 51:696-706. 10.1002/gcc.21956, 22454324.
31. Mosca L, Musto P, Todoerti K, Barbieri M, Agnelli L, Fabris S, Tuana G, Lionetti M, Bonaparte E, Sirchia SM, et al. Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles. Am J Hematol 2013, 88:16-23. 10.1002/ajh.23339, 23044976.
32. Zismanov V, Drucker L, Attar-Schneider O, Matalon ST, Pasmanik-Chor M, Lishner M. Tetraspanins stimulate protein synthesis in myeloma cell lines. J Cell Biochem 2012, 113:2500-2510. 10.1002/jcb.24126, 22415769.
33. Yamasaki S, Anderson P. Reprogramming mRNA translation during stress. Curr Opin Cell Biol 2008, 20:222-226. 10.1016/j.ceb.2008.01.013, 2841789, 18356035.
34. Silvera D, Formenti SC, Schneider RJ. Translational control in cancer. Nat Rev Cancer 2010, 10:254-266. 10.1038/nrc2824, 20332778.
35. Tamura K, Makino A, Hullin-Matsuda F, Kobayashi T, Furihata M, Chung S, Ashida S, Miki T, Fujioka T, Shuin T, et al. Novel lipogenic enzyme ELOVL7 is involved in prostate cancer growth through saturated long-chain fatty acid metabolism. Cancer Res 2009, 69:8133-8140. 10.1158/0008-5472.CAN-09-0775, 19826053.
36. Camps J, Pitt JJ, Emons G, Hummon AB, Case CM, Grade M, Jones TL, Nguyen QT, Ghadimi BM, Beissbarth T, et al. Genetic amplification of the NOTCH modulator LNX2 upregulates the WNT/beta-catenin pathway in colorectal cancer. Cancer Res 2013, 73:2003-2013. 10.1158/0008-5472.CAN-12-3159, 23319804.
37. van Delft FW, Horsley S, Colman S, Anderson K, Bateman C, Kempski H, Zuna J, Eckert C, Saha V, Kearney L, et al. Clonal origins of relapse in ETV6-RUNX1 acute lymphoblastic leukemia. Blood 2011, 117:6247-6254. 10.1182/blood-2010-10-314674, 21482711.
38. Miyata Y, Liu Y, Jankovic V, Sashida G, Lee JM, Shieh JH, Naoe T, Moore M, Nimer SD. Cyclin C regulates human hematopoietic stem/progenitor cell quiescence. Stem Cells 2010, 28:308-317. 3144254, 19967789.
39. Steen H, Lindholm D. Nuclear localized protein-1 (Nulp1) increases cell death of human osteosarcoma cells and binds the X-linked inhibitor of apoptosis protein. Biochem Biophys Res Commun 2008, 366:432-437. 10.1016/j.bbrc.2007.11.146, 18068114.
40. Veitia RA, Bottani S, Birchler JA. Cellular reactions to gene dosage imbalance: genomic, transcriptomic and proteomic effects. Trends Genet 2008, 24:390-397. 10.1016/j.tig.2008.05.005, 18585818.
41. Vazquez-Mena O, Medina-Martinez I, Juarez-Torres E, Barron V, Espinosa A, Villegas-Sepulveda N, Gomez-Laguna L, Nieto-Martinez K, Orozco L, Roman-Basaure E, et al. Amplified genes may be overexpressed, unchanged, or downregulated in cervical cancer cell lines. PLoS One 2012, 7:e32667. 10.1371/journal.pone.0032667, 3296745, 22412903.
42. Wang RT, Ahn S, Park CC, Khan AH, Lange K, Smith DJ. Effects of genome-wide copy number variation on expression in mammalian cells. BMC Genomics 2011, 12:562. 10.1186/1471-2164-12-562, 3287593, 22085887.
43. Cotter TG. Apoptosis and cancer: the genesis of a research field. Nat Rev Cancer 2009, 9:501-507. 10.1038/nrc2663, 19550425.